Cullinan Oncology (NASDAQ:CGEM) and Terns Pharmaceuticals (NASDAQ:TERN) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their analyst recommendations, risk, earnings, profitability, dividends, valuation and institutional ownership.
Profitability
This table compares Cullinan Oncology and Terns Pharmaceuticals' net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets |
---|
Cullinan Oncology | N/A | N/A | N/A |
Terns Pharmaceuticals | N/A | N/A | N/A |
Analyst Ratings
This is a breakdown of recent ratings and price targets for Cullinan Oncology and Terns Pharmaceuticals, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score |
---|
Cullinan Oncology | 0 | 1 | 3 | 0 | 2.75 |
Terns Pharmaceuticals | 0 | 0 | 3 | 0 | 3.00 |
Cullinan Oncology presently has a consensus price target of $48.25, suggesting a potential upside of 61.53%. Terns Pharmaceuticals has a consensus price target of $30.50, suggesting a potential upside of 71.93%. Given Terns Pharmaceuticals' stronger consensus rating and higher possible upside, analysts clearly believe Terns Pharmaceuticals is more favorable than Cullinan Oncology.
Valuation and Earnings
This table compares Cullinan Oncology and Terns Pharmaceuticals' top-line revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio |
---|
Cullinan Oncology | N/A | N/A | N/A | N/A | N/A |
Terns Pharmaceuticals | N/A | N/A | N/A | N/A | N/A |
Summary
Terns Pharmaceuticals beats Cullinan Oncology on 2 of the 2 factors compared between the two stocks.